I am far from an expert, but I suspect the company has already completed what it needs to do for pre-clinical work. I think the meeting with the FDA for Phase 3 design for Phelan McDermid Syndrome is the one of the most important milestones but because it affects a lot of other designs and how additional Phase 2 trials will be run. I suspect they won't make the additional indications known publicly until all the groundwork for those Phase 2 trials have been done (and this happens after discussing what they need to in terms of safety profile with the FDA). My guess is by Q4 of this calendar year. By then we'll know the trial design and what the FDA wants for P3 and how the improved protocol can be applied to Angelman + the other indications.
- Forums
- ASX - By Stock
- Share Price
I am far from an expert, but I suspect the company has already...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B |
Open | High | Low | Value | Volume |
$20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1378 | $21.24 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.29 | 218 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 21.240 |
1 | 47 | 21.150 |
1 | 500 | 20.860 |
1 | 240 | 20.800 |
1 | 50 | 20.630 |
Price($) | Vol. | No. |
---|---|---|
21.300 | 12763 | 1 |
21.350 | 30 | 1 |
21.380 | 471 | 1 |
21.410 | 25 | 1 |
21.500 | 60 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online